Beyond Air, Inc.XAIR

Health Care · Health Care Equipment & Services · NASDAQ · United States · beyondair.net

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure.

Key ratios

FCF / Sales

-255.0%TTM

2026 -249.6%2025 -1190.3%2024 -5328.7%

ROA

-57.5%TTM

2026 -55.5%2025 -64.0%2024 -62.7%

ROE

-519.5%TTM

2026 -334.1%2025 -233.5%2024 -185.8%

Revenue growth

60.8%TTM

2026 107.3%2025 219.7%

Recent news

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) 2026-08-31 · GlobeNewswire

Track XAIR in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer